Journal Information
Vol. 35. Issue 7 - 8.
Pages 447.e1-447.e3 (July - August 2016)
Share
Share
Download PDF
More article options
Visits
5315
Vol. 35. Issue 7 - 8.
Pages 447.e1-447.e3 (July - August 2016)
Case report
Open Access
Rivaroxaban for the treatment of saphenous vein graft thrombosis
O rivaroxabano no tratamento da trombose do enxerto de veia safena
Visits
5315
Konstantinos Marmagkiolisa, Mehmet Cilingiroglub,c,
Corresponding author
cilingiroglumehmet@gmail.com

Corresponding author.
a Citizens Memorial Hospital, Heart and Vascular Institute, Bolivar, MO, USA
b Arkansas Heart Hospital/University of Arkansas for Medical Sciences, Little Rock, AR, USA
c Koc University, School of Medicine, Istanbul, Turkey
This item has received

Under a Creative Commons license
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Abstract

Thrombus formafigtion plays a significant role in disease of saphenous vein bypass grafts. Use of oral anticoagulants has not been tested in treatment of thrombotic occlusion of saphenous vein graft (SVG) disease. Here we describe the use of the novel oral anticoagulant rivaroxaban in the treatment of occlusive SVG disease with intraluminal thrombus, leading to successful recanalization.

Keywords:
Saphenous vein graft disease
Thrombus
Anticoagulant
Resumo

A formação de trombos tem um papel significativo na doença do bypass do enxerto da veia safena (EVS). A utilização de anticoagulantes orais não foi testada no tratamento da oclusão trombótica na doença do EVS. Apresentamos o uso de um novo anticoagulante oral, o rivaroxabano, no tratamento da doença oclusiva do EVS com trombo intraluminal e recanalização bem-sucedida.

Palavras-chave:
Doença do enxerto da veia safena
Trombose
Anticoagulantes
Full Text
Case report

A 67-year-old woman with a history of coronary artery bypass grafting (CABG) six months previously underwent coronary angiography for stable class III angina. Extensive thrombus burden was visualized in the mid-distal segment of the saphenous vein graft (SVG) to the second obtuse marginal branch with decreased Thrombolysis In Myocardial Infarction (TIMI) 2 flow (Figures 1 and 2) and without evidence of obstructive atherosclerosis. The patient was placed on oral anticoagulation with rivaroxaban (Janssen Pharmaceuticals, Titusville, NJ, USA) 20 mg once daily. Follow-up catheterization after four weeks revealed angiographic resolution of the thrombus with significantly improved TIMI 3 flow (Figures 3 and 4).

Figure 1.

Saphenous vein graft to second obtuse marginal at baseline, in left anterior oblique view.

(0.16MB).
Figure 2.

Saphenous vein graft to second obtuse marginal at baseline, in right anterior oblique view.

(0.16MB).
Figure 3.

Saphenous vein graft to second obtuse marginal four weeks after rivaroxaban, in left anterior oblique view.

(0.16MB).
Figure 4.

Saphenous vein graft to second obtuse marginal four weeks after rivaroxaban, in right anterior oblique view.

(0.16MB).

Rivaroxaban is a new oral anticoagulant, a direct factor Xa inhibitor which is currently FDA approved for the prevention and treatment of venous thromboembolism, and for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation.1 ATLAS ACS 2-TIMI 51 demonstrated reduced risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke in patients with a recent acute coronary syndrome placed on rivaroxaban at the expense of increased risk of non-fatal major bleeding and intracranial hemorrhage.2 Thrombosis, intimal hyperplasia and atherosclerosis are the common mechanisms of SVG disease and occlusion; however, the Post CABG trial failed to demonstrate higher SVG primary patency rates with low-dose anticoagulation with warfarin as a primary prevention strategy.3 This case highlights the potential benefit of the new-generation oral anticoagulants in the secondary prevention and treatment of saphenous vein thrombosis-related disease. A similar approach was reported by Fiorina et al. in a small case series of 14 patients with non-ST-elevation myocardial infarction and occluded SVGs, in which after angioplasty with an undersized balloon to achieve TIMI flow 1-2, patients were placed on anticoagulation with warfarin for 11±7 days. A follow-up angiogram revealed that all the SVGs were patent, 14% of them with no residual lesions.4

Ethical disclosuresProtection of human and animal subjects

The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data

The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent

The authors declare that no patient data appear in this article.

Conflicts of interest

The authors have no conflicts of interest to declare.

References
[1]
C. Costopoulos, M. Niespialowska-Steuden, N. Kukreja, et al.
Novel oral anticoagulants in acute coronary syndrome.
Int J Card, (2012),
[Epub ahead of print]
[2]
J.L. Mega, E. Braunwald, S.D. Wiviott, et al.
Rivaroxaban in patients with recent acute coronary syndrome.
N Engl J Med, 366 (2012), pp. 9-19
[3]
The Post CABG Investigators.
The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
N Engl J Med, 336 (1997), pp. 153-162
[4]
C. Fiorina, E. Meliga, G. Chizzola, et al.
Early experience with a new approach for percutaneous intervention of totally occluded saphenous vein graft: is the flow the best thrombolytic?.
EuroIntervention, 6 (2010), pp. 461-466
Copyright © 2016. Sociedade Portuguesa de Cardiologia
Download PDF
Idiomas
Revista Portuguesa de Cardiologia (English edition)
Article options
Tools
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

By checking that you are a health professional, you are stating that you are aware and accept that the Portuguese Journal of Cardiology (RPC) is the Data Controller that processes the personal information of users of its website, with its registered office at Campo Grande, n.º 28, 13.º, 1700-093 Lisbon, telephone 217 970 685 and 217 817 630, fax 217 931 095, and email revista@spc.pt. I declare for all purposes that the information provided herein is accurate and correct.